Rosai-Dorfman disease: A rare presentation as an isolated axillary lymphadenopathy, a case report and literature review
Authors:
Open Access
- 1 January 2025
- journal article
- research article
- Published by Wolters Kluwer Health in International Journal of Surgery Case Reports
- Vol. 126 (C) , 110762
Abstract
Introduction: Rosai-Dorfman disease (RDD) is a rare histiocytic neoplasm. It most commonly presents with bilateral cervical lymphadenopathy. We report the fourth case in the literature of RDD presenting as isolated axillary lymphadenopathy. Case report: We report the case of a 55-year-old female patient who presented with right axillary lymphadenopathy that had persisted for 1 year, without other associated symptoms. Physical examination revealed an isolated right axillary lymphadenopathy. An excisional biopsy of the lymph node was performed, and histopathological findings were consistent with Rosai-Dorfman's disease. Regular follow-up was recommended. Discussion: RDD is an uncommon histiocytic disorder. Initially identified in the 1960s as a benign, self-limited condition, RDD is now classified as a neoplastic disorder with causative mutations in the MAPK pathway. The classic presentation involves extensive, painless bilateral cervical lymphadenopathy. Isolated axillary lymph node involvement, as seen in our patient, is a rare presentation of nodal RDD with only three cases reported in the literature to date. Histologically, RDD is characterized by a prominent histiocytic infiltrate set against a background of inflammatory cells, primarily composed of lymphocytes and plasma cells. These histiocytes are typically hypochromatic, with abundant pale cytoplasm, and exhibit varying degrees of emperipolesis. In 2018, consensus guidelines for the management and evaluation of RDD were introduced. Conclusion: Recent advances in genetic sequencing have reclassified RDD from a benign inflammatory disorder to a histiocytic neoplasm. Further research is needed to fully understand its implications for prognosis and treatment strategies. Highlights:Keywords
This publication has 16 references indexed in Scilit:
- How I Diagnose Rosai-Dorfman DiseaseAmerican Journal of Clinical Pathology, 2023
- The SCARE 2023 guideline: updating consensus Surgical CAse REport (SCARE) guidelinesInternational Journal of Surgery, 2023
- The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic NeoplasmsLeukemia, 2022
- Rosai-Dorfman disease: an overviewJournal of Clinical Pathology, 2020
- Management and outcomes of sinus histiocytosis with massive lymphadenopathy (Rosai Dorfman Disease)Leukemia & Lymphoma, 2019
- Fine-needle aspiration specimens of 3 cases of intra-abdominal Rosai-Dorfman disease with comprehensive review of the literatureJournal of the American Society of Cytopathology, 2019
- Mutually exclusive recurrent KRAS and MAP2K1 mutations in Rosai–Dorfman diseaseLaboratory Investigation, 2017
- Diverse and Targetable Kinase Alterations Drive Histiocytic NeoplasmsCancer Discovery, 2016
- Updates on histiocytic disordersPediatric Blood & Cancer, 2014
- Treatment of sinus histiocytosis with massive lymphadenopathy (rosai‐dorfman disease): Report of a case and literature reviewAmerican Journal of Hematology, 2001